Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

• Conditions: Leukemia

• Registration Number: NCT00006097
• Lead Sponsor: Boston Medical Center

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I/II trial to study the effectiveness of CC-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.

Detailed Description

OBJECTIVES: I. Determine the toxicity of CC-1088 in patients with refractory, progressive, B-cell chronic lymphocytic leukemia. II. Determine the response rate to this treatment in these patients.

OUTLINE: Patients receive oral CC-1088 three times a day for 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 11-20 patients will be accrued for this study.

Study Timeline

• Study Start: 1999-08
• Study First Submitted: 2000-08-03
• Status Verified: 2001-05
• Study First Submitted QC: 2004-05-03
• Study First Posted: 2004-05-04
• Primary Completion: 2005-07
• Study Completion: 2005-07
• Last Update Submitted: 2010-09-21
• Last Update Posted: 2010-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Boston Medical Center; 🇺🇸 Boston, Massachusetts, United States